New drug combo aims to tackle Hard-to-Treat HER2 cancers

NCT ID NCT07646626

First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This Phase 2 trial is testing two experimental drugs (SSGJ-705 and SSGJ-612) with or without chemotherapy in 150 adults with advanced HER2-positive solid tumors, including colorectal, bladder, breast, bile duct, and stomach cancers. The goal is to see if the combination can shrink tumors and control the disease longer than current options. Participants must have tumors that cannot be removed by surgery or have spread.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SSGJ-705 (a bispecific antibody targeting PD-1 and HER2) and SSGJ-612 (an anti-HER2 antibody), with or without chemotherapy
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced HER2-positive cancers that have stopped responding to standard therapies.
What could go wrong
This is a mid-stage (Phase 2) trial with only 150 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors in many patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.